Oruka Therapeutics Reports Positive Phase 2a Results for Psoriasis Treatment ORKA-001
Oruka Therapeutics (NASDAQ:ORKA) announced positive Phase 2a trial results for its psoriasis treatment ORKA-001, with 63.5% of patients achieving complete skin clearance by Week 16. The drug showed a favorable safety profile and potential for once-yearly dosing, which could redefine treatment standards. The company plans to release 52-week data in H2 2026 and advance to Phase 2b trials.
Tickers: $ORKA
Topics: biopharmaceuticals clinical trial results drug development monoclonal antibodies psoriasis treatment